<DOC>
	<DOCNO>NCT01457339</DOCNO>
	<brief_summary>This multiple ascend dose study ; purpose study examine safety , tolerability pharmacokinetics ( level drug blood ) SPD489 Schizophrenic Patients currently maintain stable dose antipsychotic medication .</brief_summary>
	<brief_title>Assess Safety Pharmacokinetics Ascending , Multiple Oral Doses SPD489 Adults With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Subjects must diagnose schizophrenia , stable dose antipsychotic cardiac risk factor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>